Somewhat Positive News Coverage Somewhat Unlikely to Affect MEI Pharma (MEIP) Stock Price
News headlines about MEI Pharma (NASDAQ:MEIP) have been trending somewhat positive on Thursday, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. MEI Pharma earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.883890787883 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of MEI Pharma (MEIP) opened at $2.22 on Thursday. MEI Pharma has a 1 year low of $1.34 and a 1 year high of $3.26.
MEI Pharma (NASDAQ:MEIP) last released its quarterly earnings data on Tuesday, September 5th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. The company had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.60 million. MEI Pharma had a negative return on equity of 3.62% and a negative net margin of 8.24%. equities research analysts anticipate that MEI Pharma will post -1.05 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/30/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-mei-pharma-meip-stock-price.html.
MEI Pharma Company Profile
MEI Pharma, Inc is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Receive News & Stock Ratings for MEI Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma Inc and related stocks with our FREE daily email newsletter.